


Background


1. Cytokine-induced killer (CIK) cells are demonstrated to have potent cytolytic effect against ovarian cancer cells *in vitro* and *in vivo*.
2. The clinical efficacy of maintenance therapy of CIK cells in patients with epithelial ovarian cancer (EOC) after first-line treatment remains unclear.

Results


1. Phenotypic analysis of immune cells after expansion and Characteristics of Cultured CIK cells.




The percentage of CIK cells ($CD3^+CD8^+D56^+$) after 14-d induction from the patient.




2. CIT prolonged survival of patients with EOC




3. Subgroup analysis to estimate the benefits of OS from adjuvant CIT.



4. Effects of CIK cell phenotype on survival in the patients.



CIK cell treatment assignment procedure



Conclusions

Adjuvant CIT with CIK cells, especially when comprised of more $CD8^+$ T cells or NKT cells, is an effective therapeutic approach to prolonging the survival of EOC patients.